PGP and carcinoma: Likewise, a strategy we have used to upgrade our anticancer assay is to source and screen against a MDR carcinoma cell line overexpressing the drug efflux pump P-glycoprotein (P-gp) the goal being to discover a non-cytotoxic natural product capable of reversing the P-gp mediated MDR phenotype.